image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 7.55
2.03 %
$ 194 M
Market Cap
-12.38
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one NEO stock under the worst case scenario is HIDDEN Compared to the current market price of 7.55 USD, NeoGenomics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one NEO stock under the base case scenario is HIDDEN Compared to the current market price of 7.55 USD, NeoGenomics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one NEO stock under the best case scenario is HIDDEN Compared to the current market price of 7.55 USD, NeoGenomics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NEO

image
$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
661 M REVENUE
11.65%
-92.1 M OPERATING INCOME
14.51%
-78.7 M NET INCOME
10.51%
7.02 M OPERATING CASH FLOW
459.60%
12.9 M INVESTING CASH FLOW
-83.24%
4.65 M FINANCING CASH FLOW
2.02%
168 M REVENUE
-2.31%
-27.8 M OPERATING INCOME
-51.21%
-25.9 M NET INCOME
-69.17%
-25.3 M OPERATING CASH FLOW
-258.44%
3.56 M INVESTING CASH FLOW
165.12%
949 K FINANCING CASH FLOW
38.14%
Balance Sheet NeoGenomics, Inc.
image
Current Assets 596 M
Cash & Short-Term Investments 387 M
Receivables 151 M
Other Current Assets 58.6 M
Non-Current Assets 1.04 B
Long-Term Investments 0
PP&E 174 M
Other Non-Current Assets 868 M
23.62 %9.19 %3.58 %10.60 %53.01 %Total Assets$1.6b
Current Liabilities 301 M
Accounts Payable 21.6 M
Short-Term Debt 201 M
Other Current Liabilities 78.9 M
Non-Current Liabilities 434 M
Long-Term Debt 340 M
Other Non-Current Liabilities 94.1 M
2.94 %27.29 %10.72 %46.26 %12.79 %Total Liabilities$735.7m
EFFICIENCY
Earnings Waterfall NeoGenomics, Inc.
image
Revenue 661 M
Cost Of Revenue 370 M
Gross Profit 290 M
Operating Expenses 376 M
Operating Income -92.1 M
Other Expenses -13.4 M
Net Income -78.7 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)661m(370m)290m(376m)(92m)13m(79m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
43.92% GROSS MARGIN
43.92%
-13.94% OPERATING MARGIN
-13.94%
-11.92% NET MARGIN
-11.92%
-8.72% ROE
-8.72%
-4.81% ROA
-4.81%
-5.85% ROIC
-5.85%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis NeoGenomics, Inc.
image
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -78.7 M
Depreciation & Amortization 72.5 M
Capital Expenditures -41.1 M
Stock-Based Compensation 33.4 M
Change in Working Capital 0
Others -26.8 M
Free Cash Flow -34 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets NeoGenomics, Inc.
image
Wall Street analysts predict an average 1-year price target for NEO of $16.3 , with forecasts ranging from a low of $12 to a high of $19 .
NEO Lowest Price Target Wall Street Target
12 USD 58.94%
NEO Average Price Target Wall Street Target
16.3 USD 116.34%
NEO Highest Price Target Wall Street Target
19 USD 151.66%
Price
Max Price Target
Min Price Target
Average Price Target
2020181816161414121210108866Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.4 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.50.50.40.40.30.30.30.30.30.30.20.20.10.10.10.10.10.10.00.00.40.4020202020
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership NeoGenomics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
79.5 K USD 1
9-12 MONTHS
16.7 K USD 1
Bought
585 K USD 8
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ: NEO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025 FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. businesswire.com - 1 week ago
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, with the option to add HRD testing. businesswire.com - 1 week ago
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. businesswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. (“Zeo” or the “Company”) (NASDAQ: NEO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 2 weeks ago
NEO Battery Materials Announces Closing of First Tranche of Private Placement TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the closing of the first tranche (the “First Tranche”) of a non-brokered private placement (the “Offering”) through the issuance of 400,000 units (each, a “Unit”) at a price of $0.50 CAD per Unit (the “Offering Price”) for aggregate gross proceeds of $200,000 CAD. globenewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ: NEO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ:NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. (“Zeo” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ:NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ: NEO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ:NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 4 weeks ago
8. Profile Summary

NeoGenomics, Inc. NEO

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 194 M
Dividend Yield 0.00%
Description NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Contact 9490 NeoGenomics Way, Fort Myers, FL, 33912 https://www.neogenomics.com
IPO Date March 16, 2004
Employees 2200
Officers Dr. Andrew A. Lukowiak Ph.D. Chief Innovation Officer Ms. Alicia C. Olivo Executive Vice President of Business Development, General Counsel & Corporate Secretary Mr. Gregory D. Aunan Senior Vice President & Chief Accounting Officer Mr. Hutan Hashemi J.D. Chief Compliance Officer Mr. Warren Stone President & Chief Operating Officer Mr. Gary Passman Chief People & Culture Officer Mr. Anthony P. Zook Chief Executive Officer & Director Mr. Kareem M. Saad Head of Strategy, Business Development & Transformation Mr. Jeffrey S. Sherman M.B.A. Chief Financial Officer Ms. Kendra Sweeney Vice President of Investor Relations & Communications